Clinical Handbook of Psychotropic Drugs
PUB
Produktinformationen "Clinical Handbook of Psychotropic Drugs"
A new edition is in preparation
Quick and comprehensive information on psychotropic drugs for adults.
- Accurate and up-to-date
- Comparison charts help decision-making
- Icons with full color
- Available both in print and online
- Downloadable patient information sheets
More about this book
The Clinical Handbook of Psychotropic Drugs has become a standard reference and working tool for psychiatrists, psychologists, physicians, pharmacists, nurses, and other mental health professionals.
- Independent, unbiased, up-to-date
- Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions…) for a quick overview of treatment options
- Succinct, bulleted information on all classes of medication: on- and off-label indications, (US FDA, Health Canada), recommended dosages, US and Canadian trade names, side effects, interactions, pharmacodynamics, precautions in the young, the elderly, and pregnancy, nursing implications, and much more – all you need to know for each class of drug
- Potential interactions and side effects summarized in comparison charts
- With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek
- Clearly written patient information sheets available for download as printable PDF files
This book is a must for everyone who needs an up-to-date, easy-to-use, comprehensive summary of all the most relevant information about psychotropic drugs.
New in this edition
- Antidepressants chapter includes a new section on the NMDA receptor antagonist/CYP2D6 inhibitor combination product (dextromethorphan/bupropion)
- Antipsychotics updates include revised clozapine monitoring tables which now also contain monitoring requirements for patients with or without non-benign ethnic neutropenia
- Mood Stabilisers sections on Lithium and Anticonvulsants extensively revised
- Dementia chapter includes a new section on lecanemab, a new fast-track FDA-approved treatment for Alzheimer’s disease
- Treatment of Substance Use Disorders includes revisions to buprenorphine dosing section that include a rapid micro-induction method (Bernese method) that allows treatment to start without waiting for patient to be in withdrawal
- Unapproved treatments of Psychiatric Disorders, Natural Health Products, and Pharmacogenetics chapters all substantially revised
- New formulations and trade names include: Auvelity (dextromethorphan/bupropion extended-release tablets), Invega Hafyera (paliperidone 6-monthly IM injection), Leqembi (lecanemab infusion), Subutex (buprenorphine sublingual tablets), Quviviq (daridorexant tablets)
| product_form: | BUCH |
|---|
Anmelden